Special Awards In Pictures

Russia's Gam-Evac Combi is the world's first officially registered vaccine approved for clinical use for the prevention of hemorrhagic fever caused by the Ebola virus.  According to Russian Health Minister, Veronika Skvortsova, the Russian vaccine has proved its effectiveness and has practically no side effects.

In 2014, nearly 2,500 people in Guinea died in an Ebola virus outbreak. The West African Ebola virus epidemic (2013–2016) was the most widespread outbreak of Ebola virus disease (EVD) in history causing major loss of life and socioeconomic disruption in the region, mainly in the countries of Guinea, Liberia, and Sierra Leone.

The first cases were recorded in Guinea in December 2013; later, the disease spread to neighboring Liberia and Sierra Leone, with minor outbreaks occurring elsewhere. It caused significant mortality, with the case fatality rate reported at slightly above 70%, while the rate among hospitalized patients was 57–59%.

Small outbreaks occurred in Nigeria and Mali, and isolated cases were recorded in Senegal, the United Kingdom and Sardinia. In addition, imported cases led to secondary infection of medical workers in the United States and Spain, but did not spread further. The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources.

As of 8 May 2016, the World Health Organization (WHO) and respective governments reported a total of 28,616 suspected cases and 11,310 deaths (39.5%), though the WHO believes that this substantially understates the magnitude of the outbreak.

The outbreak left about 17,000 survivors of the disease, many of whom report post-recovery symptoms termed post-Ebola syndrome, often severe enough to require medical care for months or even years. An additional cause for concern is the apparent ability of the virus to "hide" in a recovered survivor's body for an extended period of time and then become active months or years later, either in the same individual or in a sexual partner.

In December 2016, the WHO announced that a two-year trial of the rVSV-ZEBOV vaccine appeared to offer protection from the strain of Ebola responsible for the West Africa outbreak.

Who we are

We dedicate time, energy, resources in the people who go out for the news.  We invest  in the  talents  and potentials of  the   professionals.  Basically, we focus on   capacity  building of our  people so that they can be prepared for the challenges ahead. We are the light for all. We  focus on the needs of our readers and bring to them new  level of  innovation that inspires them.

What we do

New Republic  tells the accurate stories as they come.  Investigate, capture moments and tell it as it comes. We bring to readers what  is news, what is informative and what is touching to add value to their business and  time. Importantly,  we do the job as our clients and readers would like to see. Moreover,  value  is added to whatever that we do to enhance productivity and longevity.

How we do it

We dedicate time, energy, resources in the people who go out for the news.  We invest  in the  talents  and potentials of  the   professionals. We look at the issues that make the news and bring  it to  our readers. The way of working is very unique and professional. Looking beyond the news is always our aim. Knowing what is behind the news is  crucial in all that we do.

When we do it

We do it just it  as it comes.  We get it out in a more  balanced and professional way as expected by the professionals  straight to  our readers. We do it at a time when  others do   not have it in mind. While others are searching, thinking, that is the time we release it to  our  readers. So, it comes at a privileged time where they will make  an  opinion on relevant issues.